HTG Molecular Diagnostics (HTGMQ) Stock Price, News & Analysis

Company Overview

HTG Molecular Diagnostics was a life sciences company headquartered in Tucson, Arizona, focused on the development and commercialization of sample-to-answer molecular profiling systems. The company’s core offering centered on its proprietary HTG Edge system, an automated, extraction-free workflow designed for targeted RNA and DNA assays. Leveraging nuclease protection chemistry, the platform enabled precise gene expression measurement directly from challenging sample types such as formalin-fixed, paraffin-embedded tissues.

HTG marketed a suite of companion assay panels and reagent kits tailored for applications in oncology, immuno-oncology and infectious disease research. Through collaborations with pharmaceutical firms, contract research organizations and academic institutions, the company’s technologies were deployed to accelerate biomarker discovery, support patient stratification in clinical trials and streamline translational research efforts. The compatibility of HTG’s assays with next-generation sequencing instruments further broadened their appeal in both preclinical and clinical research settings.

Founded in 2005, HTG Molecular Diagnostics completed its initial public offering on the Nasdaq exchange in 2015 under the ticker HTGM. In December 2022, the company filed for Chapter 7 bankruptcy and initiated the liquidation of its assets under the HTGMQ designation. Prior to winding down operations, HTG’s distribution network reached customers across North America, Europe and select markets in Asia, reflecting its historical role in advancing automated molecular diagnostic solutions for the global research community.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.01
• Volume: 502 shs
• Average Volume: 1,510 shs
• Market Capitalization: $221.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HTGMQ Stock Analysis - Frequently Asked Questions

How have HTGMQ shares performed this year?

HTG Molecular Diagnostics' stock was trading at $0.0001 at the start of the year. Since then, HTGMQ shares have increased by 0.0% and is now trading at $0.0001.

How do I buy shares of HTG Molecular Diagnostics?

Shares of HTGMQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:HTGMQ
• CIK: 1169987
• Web: www.htgmolecular.com
• Phone: 877-289-2615
• Fax: 520-547-2837
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $6.37 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,210,000
• Free Float: 2,156,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 2.67